Literature DB >> 26289418

Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.

Laure Ecotière1, Antoine Thierry1, Céline Debiais-Delpech2, Sylvie Chevret3, Vincent Javaugue1, Estelle Desport1, Simohamed Belmouaz1, Nathalie Quellard2, Sihem Kaaki2, Jean Michel Goujon2, Jean-Paul Fermand4, Guy Touchard1, Frank Bridoux1.   

Abstract

BACKGROUND: Light chain myeloma cast nephropathy (MCN) is the major cause of renal failure in multiple myeloma and strongly impacts patient survival. The role of kidney biopsy in the management of MCN is unclear.
METHODS: Renal pathological findings were retrospectively studied in 70 patients with multiple myeloma and MCN. Patients were categorized according to the achievement or not of renal response, as defined by estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m(2) and/or dialysis independence at 3 months.
RESULTS: Thirty-two patients (46%) achieved a renal response. In the whole study population, the following parameters differed significantly between patients with and without renal response, respectively: baseline median eGFR (13.3 versus 9.3 mL/min/1.73 m(2), P = 0.017), Acute Kidney Injury Network Stage 3 (68.8 versus 92.1%, P = 0.019), haematological response rate (94 versus 34%, P < 0.0001), median percentage of free light chain (FLC) reduction at Day 21 (92 versus 24%, P = 0.006) and median number of casts/10 fields (14 versus 25, P = 0.005). The extent of interstitial fibrosis and tubular atrophy was similar. In multivariate analysis, only FLC reduction at Day 21 was significantly associated with renal response. However, when considering only the subgroup of haematological responders, both median number of casts [odds ratio (OR) = 0.93, 95% confidence interval (95% CI): 0.88-0.98, P = 0.01] and extent of tubular atrophy (OR = 0.03, 95% CI: 0.00-0.52, P = 0.02) were independent predictors of renal response.
CONCLUSIONS: In MCN, the presence of numerous casts and diffuse tubular atrophy is associated with poor renal prognosis. These data suggest that additional strategies to reduce FLC burden should be considered in patients with extensive cast formation.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  acute kidney injury; dialysis; immunoglobulin light chains; kidney biopsy; myeloma cast nephropathy

Mesh:

Year:  2015        PMID: 26289418     DOI: 10.1093/ndt/gfv283

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Authors:  Frank Bridoux; Pierre-Louis Carron; Brigitte Pegourie; Eric Alamartine; Karine Augeul-Meunier; Alexandre Karras; Bertrand Joly; Marie-Noëlle Peraldi; Bertrand Arnulf; Cécile Vigneau; Thierry Lamy; Alain Wynckel; Brigitte Kolb; Bruno Royer; Nolwenn Rabot; Lotfi Benboubker; Christian Combe; Arnaud Jaccard; Bruno Moulin; Bertrand Knebelmann; Sylvie Chevret; Jean-Paul Fermand
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

2.  Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).

Authors:  Hannah Tessenow; Madlen Holzvogt; Bruno Holzvogt; Marc Andrea; Simone Heyn; Thomas Schliwa; Maik Schwarz; Thomas Zehrfeld; Cornelia Becker; Christian Pfrepper; Georg Nikolaus Franke; Rainer Krahl; Madlen Jentzsch; Sabine Leiblein; Sebastian Schwind; Marius Bill; Vladan Vucinic; Thoralf Lange; Dietger Niederwieser; Wolfram Pönisch
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-22       Impact factor: 4.553

3.  A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study.

Authors:  Zi-Shan Lin; Ai-Bo Qin; Su-Xia Wang; Xiao-Juan Yu; Bao Dong; Zu-Ying Xiong; Meng-Hua Chen; Fu-De Zhou; Ming-Hui Zhao
Journal:  J Nephrol       Date:  2021-01-04       Impact factor: 3.902

Review 4.  Indications and considerations for kidney biopsy: an overview of clinical considerations for the non-specialist.

Authors:  Katherine L Hull; Sherna F Adenwalla; Peter Topham; Matthew P Graham-Brown
Journal:  Clin Med (Lond)       Date:  2021-12-17       Impact factor: 2.659

Review 5.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

Review 6.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

7.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

8.  Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.

Authors:  Hiroyuki Ueda; Hideaki Kuno; Daisuke Takahashi; Ai Katsuma; Ai Kimura; Akio Nakashima; Junichiro Kato; Mamiko Momoki; Rie Ohba; Nobuaki Dobashi; Izumi Yamamoto; Tetsuya Kawamura; Yoichi Miyazaki; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2020-01-23

9.  Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis.

Authors:  Jean-Baptiste Gibier; Viviane Gnemmi; François Glowacki; Eileen M Boyle; Benjamin Lopez; Evelyne MacNamara; Maxime Hoffmann; Raymond Azar; Thomas Guincestre; Franck Bourdon; Marie-Christine Copin; David Buob
Journal:  Mod Pathol       Date:  2017-10-20       Impact factor: 7.842

10.  Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center.

Authors:  Zi-Shan Lin; Xiao-Juan Yu; Xu Zhang; Su-Xia Wang; Xi-Nan Cen; Fu-De Zhou; Ming-Hui Zhao
Journal:  Cancer Manag Res       Date:  2021-05-13       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.